FDA Sets 2027 Target Action Date for Axsome's Cataplexy Drug Candidate

The US Food and Drug Administration (FDA) has accepted a new drug application from Axsome Therapeutics Inc for AXS-12, an investigational treatment for cataplexy in narcolepsy.

New Drug Application Accepted

The FDA has accepted for filing a New Drug Application from Axsome Therapeutics Inc for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. This is a significant step forward for the treatment of cataplexy, a condition characterized by a sudden reduction or loss of muscle tone while a patient is awake.

Target Action Date Set

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. This means that the FDA aims to make a decision on the application by this date. Additionally, the agency has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application.

Investigational Drug Details

AXS-12 is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator under development for the treatment of narcolepsy. The investigational drug is thought to modulate noradrenergic activity to maintain muscle tone during wakefulness, as well as noradrenergic and cortical dopaminergic signaling to promote wakefulness and cognitive function. AXS-12 has been granted FDA Orphan Drug Designation for the treatment of narcolepsy but is not currently approved by the FDA.

Cataplexy Explained

Cataplexy involves a sudden reduction or loss of muscle tone while a patient is awake, typically triggered by strong emotions such as laughter, fear, anger, stress, or excitement. This condition can be a significant challenge for individuals with narcolepsy, and the development of effective treatments is crucial for improving their quality of life.